Pancreatic Cancer Research

ResearcherIstituto Oncologico VenetoActive in the last 2 years

Francesca Bergamo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8795-4653; OpenAlex author ID A5028325185. Sources: OpenAlex.

Their work

Papers
15 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
93
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: 3 papers · 2024: 1 paper · 2025: 2 papers · 2026: 5 papers

Papers 15

  1. Presumed Intraductal Papillary Mucinous Neoplasms in Individuals at High Risk for Pancreatic Cancer. Co-author DOI 10.1001/jamanetworkopen.2026.35610↗
  2. Impact of center-level protocol adherence on neoadjuvant treatment outcome in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejca.2026.117033↗
  3. Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection. Co-author DOI 10.1093/oncolo/oyag085↗
  4. Conversion surgery vs. standard of care in pancreaTic cancer oligometastatic to the liver (SONAR: Surgery in Oligometastatic paNcreatic cAnceR) a randomized co… Co-author DOI 10.1186/s12885-025-15183-9↗
  5. Chemotherapy for Locally Advanced Pancreatic Cancer: The Dilemma of David Versus Goliath After NEOPAN. Last author DOI 10.1200/jco-25-01517↗
  6. Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants. Co-author DOI 10.1002/cam4.70364↗
  7. A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of modified FOLFIRINOX as first-line chemothe… Co-author DOI 10.1016/j.dld.2025.11.007↗
  8. Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as second or later-line treatment. Co-author DOI 10.1002/cam4.7345↗
  9. The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.6111↗
  10. Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary a… Co-author DOI 10.1016/j.esmoop.2022.100777↗
  11. Role of Immune Microenvironment in Pancreatic Ductal Adenocarcinoma: Could It Be Considered a Predictor of Prognosis? Co-author DOI 10.3390/curroncol30060417↗
  12. An Unexpected Tumor Reduction: Treatment with Olaparib Monotherapy in Heavily Pretreated BRCA2 Mutated Metastatic Pancreatic Cancer. Co-author DOI 10.3390/curroncol29020049↗
  13. Could Total Neoadjuvant Therapy Followed by Surgical Resection Be the New Standard of Care in Pancreatic Cancer? A Systematic Review and Meta-Analysis. Co-author DOI 10.3390/jcm11030812↗
  14. The role of FDG PET/CT or PET/MRI in assessing response to neoadjuvant therapy for patients with borderline or resectable pancreatic cancer: a systematic liter… Co-author DOI 10.1007/s12149-021-01629-0↗
  15. Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial. Co-author DOI 10.1016/j.ejca.2013.06.041↗

Closest collaborators

The 25 strongest of 93 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sara Lonardi · 9 shared papers, 2022–2026 · strength 1.82
  2. Letizia Procaccio · 8 shared papers, 2022–2026 · strength 1.72
  3. Elisa Giommoni · 5 shared papers, 2023–2026 · strength 0.80
  4. Federico Nichetti · 3 shared papers, 2025–2026 · strength 0.79
  5. Mario Scartozzi · 4 shared papers, 2023–2026 · strength 0.71
  6. Michèle Milella · 5 shared papers, 2013–2026 · strength 0.69
  7. Guido Giordano · 4 shared papers, 2023–2026 · strength 0.64
  8. Mariacristina Di Marco · 3 shared papers, 2025–2026 · strength 0.58
  9. Silvia Bozzarelli · 3 shared papers, 2025–2026 · strength 0.54
  10. Ilario Giovanni Rapposelli · 3 shared papers, 2025–2026 · strength 0.54
  11. Monica Niger · 3 shared papers, 2025–2026 · strength 0.52
  12. Giampaolo Tortora · 3 shared papers, 2024–2026 · strength 0.51
  13. Enrico Vasile · 3 shared papers, 2024–2026 · strength 0.51
  14. Alberto Fantin · 3 shared papers, 2022–2026 · strength 0.50
  15. Ferdinando De Vita · 3 shared papers, 2023–2026 · strength 0.48
  16. Davide Melisi · 3 shared papers, 2023–2026 · strength 0.48
  17. Alberto Zaniboni · 3 shared papers, 2023–2026 · strength 0.48
  18. Michele Reni · 3 shared papers, 2013–2026 · strength 0.41
  19. Gabriele Capurso · 2 shared papers, 2026 · strength 0.39
  20. Massimo Falconi · 2 shared papers, 2026 · strength 0.39
  21. Paolo Giorgio Arcidiacono · 2 shared papers, 2026 · strength 0.39
  22. Marina Macchini · 2 shared papers, 2025–2026 · strength 0.38
  23. Giulia Orsi · 2 shared papers, 2025–2026 · strength 0.38
  24. Caterina Vivaldi · 2 shared papers, 2025–2026 · strength 0.36
  25. Matteo Landriscina · 2 shared papers, 2024–2026 · strength 0.35

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.